{"analyses":[{"ciLowerLimit":"-3.165","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.876","estimateComment":"Course 1","groupIds":["OG000"],"nonInferiorityComment":"The 95% confidence intervals for the difference (oral - IV) were generated using an ANOVA model separately for Course 1 and Course 2.","nonInferiorityType":"EQUIVALENCE","paramType":"Mean Difference (Final Values)","paramValue":"-0.144"},{"ciLowerLimit":"-3.463","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.288","estimateComment":"Course 2","groupIds":["OG000"],"nonInferiorityComment":"The 95% confidence intervals for the difference (oral - IV) were generated using an ANOVA model separately for Course 1 and Course 2.","nonInferiorityType":"EQUIVALENCE","paramType":"Mean Difference (Final Values)","paramValue":"-0.087"},{"ciLowerLimit":"-6.074","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.899","estimateComment":"Course 1","groupIds":["OG001"],"nonInferiorityComment":"The 95% confidence intervals for the difference (oral - IV) were generated using an ANOVA model separately for Course 1 and Course 2.","nonInferiorityType":"EQUIVALENCE","paramType":"Mean Difference (Final Values)","paramValue":"-2.588"},{"ciLowerLimit":"-5.080","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.888","estimateComment":"Course 2","groupIds":["OG001"],"nonInferiorityComment":"The 95% confidence intervals for the difference (oral - IV) were generated using an ANOVA model separately for Course 1 and Course 2.","nonInferiorityType":"EQUIVALENCE","paramType":"Mean Difference (Final Values)","paramValue":"-0.096"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.023","upperLimit":"13.294","value":"11.159"},{"groupId":"OG001","lowerLimit":"7.696","upperLimit":"12.459","value":"10.077"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Course 1 - Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.167","upperLimit":"13.439","value":"11.303"},{"groupId":"OG001","lowerLimit":"10.12","upperLimit":"15.211","value":"12.665"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Course 1 - IV Decitabine"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.446","upperLimit":"12.219","value":"9.833"},{"groupId":"OG001","lowerLimit":"4.438","upperLimit":"11.830","value":"8.134"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Course 2 - Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.534","upperLimit":"12.307","value":"9.920"},{"groupId":"OG001","lowerLimit":"4.887","upperLimit":"11.574","value":"8.230"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Course 2 - IV Decitabine"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Mean maximum % long interspread nuclear element-1 (LINE-1) demethylation after oral decitabine + cedazuridine (E7727) or ASTX727 (Course 1 or Course 2 - Treatment) compared with IV decitabine 20 mg/m\\^2 (Course 1 or Course 2 - IV Decitabine) in the dose confirmation and fixed-dose combination stages, respectively. Least squares mean of maximum %LINE-1 methylation change from baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m\\^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.","id":"OG000","title":"Phase 2 Dose Confirmation"},{"description":"Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m\\^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.","id":"OG001","title":"Phase 2 Fixed-Dose Combination"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The pharmacodynamic population includes all participants with evaluable data who received at least one dose of investigational product.","reportingStatus":"POSTED","timeFrame":"Pre-dose to Day 28 in Course 2 (28 days per course)","title":"Mean Maximum %LINE Demethylation in Phase 2","type":"PRIMARY","unitOfMeasure":"Percent"}